Why AstraZeneca PLC’s (AZN) Stock Is Up 6.88%
As of Friday, October 30, AstraZeneca PLC’s AZN share price has surged by 6.88%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
Commentary & Analysis
Which Is a Better Investment, AstraZeneca PLC or Bristol-Myers Squibb Company Stock?
Learn more about whether AstraZeneca PLC or Bristol-Myers Squibb Company is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Which Is a Better Investment, AstraZeneca PLC or Corcept Therapeutics Incorporated Stock?
Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Which Is a Better Investment, AstraZeneca PLC or Jazz Pharmaceuticals plc Stock?
Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Which Is a Better Investment, AstraZeneca PLC or Pfizer Inc. Stock?
Learn more about whether AstraZeneca PLC or Pfizer Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Financial Summary
| Share Statistics | AZN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $292,947.6 | $409.9 | 99% |
|
| Shares Out (Mil) | 1,560.0 | 44.5 | 96% |
|
| Institutional Ownership | 99.9% | 81.1% | 96% |
|
| Float (Mil) | 1,543.2 | 45.7 | 94% |
|
| Beta | 0.21 | 0.72 | 13% |
|
| Avg Daily Volume (000s) | 3,655 | 284 | 88% |
|
| Price Change (52-week) |
14.1% | 52.7% | 63% |
|
| Growth | AZN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.2% | 5.7% | 77% |
|
| Net Income (5yr) | 26.2% | (2.0%) | 81% |
|
| EPS (5yr) | 21.8% | 14.9% | 71 |
|
| Dividends (5yr) | 2.7% | 0.0% | 95% |
|
| Cash Flow (5yr) | (37.4%) | (15.1%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 2 | 3 | |
| Current EPS | $1.146 | $10.120 | $11.317 | |
| Month Ago EPS | $2.685 | $10.464 | $11.565 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | $2.685 | $10.464 | $11.580 | |
| Year/Year Chg | (42.7%) | 54.7% | 91.4% | |
| Financials | AZN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $62,384 | $326 | 97% |
|
| Net Income (TTM) (Mil) | $11,030 | ($11) | 99% |
|
| EPS (TTM) | $7.116 | ($0.600) | 91% |
|
| Operating Cash Flow (TTM) (Mil) | $13,232 | ($6) | 98% |
|
| Net Cash Flow (TTM) (Mil) | ($163) | $2 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $28,905 | $6 | 97% |
|
| Enterprise Value (Q1) (Mil) | $316,319 | $466 | 99% |
|
| Valuation | AZN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.60 | 1.96 | 83% |
|
| P/E | 26.5 | 20.1 | 68% |
|
| Dividend Yield | 1.3% | 0.0% | 69% |
|
| PEG (5yr hist) | 1.2 | 1.2 | 55% |
|
| Ratios | AZN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 81.8% | 67.7% | 90% |
|
| Net Margin | 17.7% | 3.4% | 76% |
|
| ROA | 9.4% | (21.5%) | 86% |
|
| ROE | 22.6% | (21.0%) | 82% |
|
| Liabilities to Assets | 56.8% | 31.8% | 50% |
|
| F-Score | 7 | 3 | 82% |
|
AstraZeneca PLC did not pass any screens on 11/5/2026.
